BiotechTube

INCA034176 + Best Available Therapy (BAT)

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Graft-versus-host-disease

Conditions

Chronic Graft-versus-host-disease

Trial Timeline

Jun 4, 2025 → Nov 30, 2032

NCT ID
NCT06821542

About INCA034176 + Best Available Therapy (BAT)

INCA034176 + Best Available Therapy (BAT) is a phase 3 stage product being developed by Incyte for Chronic Graft-versus-host-disease. The current trial status is active. This product is registered under clinical trial identifier NCT06821542. Target conditions include Chronic Graft-versus-host-disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06821542Phase 3Active

Competing Products

20 competing products in Chronic Graft-versus-host-disease

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74